Recent Finacing
Recent Raise
Cylene Pharmaceuticals develops targeted small-molecule oncology drugs using its STAND discovery platform; lead CX-4945 is an oral CK2 inhibitor in Phase I/II development for solid tumors and multiple myeloma.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
